Export

EN
FR
ATC codes: J04AB02
EMLc
Indication
Leprosy ICD11 code: 1B50.Z
INN
Rifampicin
Medicine type
Chemical agent
List type
Core Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance. Colour-coded blister packs (MDT blister packs) containing standard two-medicine (paucibacillary leprosy) or three-medicine (multibacillary leprosy) combination for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO.
Formulations
Oral > Solid: 150 mg solid oral dose form ; 300 mg solid oral dose form
EML status history
First added in 1977 (TRS 615)
Changed in 1982 (TRS 685)
Changed in 2003 (TRS 920)
Changed in 2007 (TRS 950)
Sex
All
Age
Also recommended for children
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
Rifampicin was endorsed as an essential medicine for the treatment of leprosy by the EMLc Subcommittee and was included on the core list of the first EMLc in 2007.